ProShare Advisors’s Myriad Genetics MYGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$60.1K Sell
13,350
-4,347
-25% -$22.6K ﹤0.01% 1767
2025
Q4
$109K Buy
17,697
+511
+3% +$3.71K ﹤0.01% 1857
2025
Q3
$124K Sell
17,186
-3,155
-16% -$18.7K ﹤0.01% 1806
2025
Q2
$108K Sell
20,341
-747
-4% -$4.41K ﹤0.01% 1868
2025
Q1
$187K Sell
21,088
-5,894
-22% -$70.8K ﹤0.01% 1713
2024
Q4
$370K Buy
26,982
+2,933
+12% +$54.1K ﹤0.01% 1478
2024
Q3
$659K Buy
24,049
+4,909
+26% +$133K ﹤0.01% 979
2024
Q2
$468K Sell
19,140
-4,853
-20% -$106K ﹤0.01% 1020
2024
Q1
$512K Buy
23,993
+2,990
+14% +$64.3K ﹤0.01% 1070
2023
Q4
$402K Buy
21,003
+3,334
+19% +$57.7K ﹤0.01% 1173
2023
Q3
$283K Sell
17,669
-244
-1% -$4.64K ﹤0.01% 1241
2023
Q2
$415K Buy
17,913
+724
+4% +$15.8K ﹤0.01% 1060
2023
Q1
$399K Sell
17,189
-2,109
-11% -$42.8K ﹤0.01% 1021
2022
Q4
$280K Buy
19,298
+1,554
+9% +$29K ﹤0.01% 1279
2022
Q3
$338K Buy
17,744
+250
+1% +$5.74K ﹤0.01% 1078
2022
Q2
$318K Sell
17,494
-8,460
-33% -$176K ﹤0.01% 1185
2022
Q1
$654K Sell
25,954
-5,128
-16% -$131K ﹤0.01% 1120
2021
Q4
$857K Buy
31,082
+2,455
+9% +$71.1K ﹤0.01% 1122
2021
Q3
$924K Sell
28,627
-7,173
-20% -$238K ﹤0.01% 930
2021
Q2
$1.09M Buy
35,800
+4,146
+13% +$120K ﹤0.01% 991
2021
Q1
$964K Buy
31,654
+2,834
+10% +$80.4K ﹤0.01% 1007
2020
Q4
$570K Buy
28,820
+6,704
+30% +$108K ﹤0.01% 1175
2020
Q3
$288K Sell
22,116
-1,928
-8% -$24.4K ﹤0.01% 1202
2020
Q2
$273K Buy
24,044
+7,079
+42% +$101K ﹤0.01% 1278
2020
Q1
$243K Sell
16,965
-12,586
-43% -$266K ﹤0.01% 941
2019
Q4
$805K Sell
29,551
-2,040
-6% -$56.1K ﹤0.01% 874
2019
Q3
$904K Sell
31,591
-991
-3% -$28.9K 0.01% 777
2019
Q2
$905K Sell
32,582
-4,841
-13% -$137K 0.01% 792
2019
Q1
$1.24M Buy
37,423
+390
+1% +$11.9K 0.01% 705
2018
Q4
$1.08M Sell
37,033
-4,317
-10% -$155K 0.01% 690
2018
Q3
$1.9M Sell
41,350
-596
-1% -$26.5K 0.01% 622
2018
Q2
$1.57M Sell
41,946
-2,654
-6% -$89.6K 0.01% 677
2018
Q1
$1.32M Sell
44,600
-6,369
-12% -$215K 0.01% 730
2017
Q4
$1.75M Buy
50,969
+5,041
+11% +$170K 0.01% 643
2017
Q3
$1.66M Buy
45,928
+2,849
+7% +$81.3K 0.02% 609
2017
Q2
$1.11M Sell
43,079
-4,068
-9% -$86.4K 0.01% 705
2017
Q1
$905K Sell
47,147
-9,875
-17% -$175K 0.01% 783
2016
Q4
$951K Buy
57,022
+4,852
+9% +$87.8K 0.01% 796
2016
Q3
$1.07M Sell
52,170
-10,747
-17% -$273K 0.02% 661
2016
Q2
$1.93M Buy
62,917
+131
+0.2% +$4.55K 0.02% 535
2016
Q1
$2.35M Sell
62,786
-6,045
-9% -$228K 0.03% 406
2015
Q4
$2.97M Buy
68,831
+7,340
+12% +$310K 0.04% 399
2015
Q3
$2.31M Sell
61,491
-6,551
-10% -$233K 0.03% 442
2015
Q2
$2.31M Buy
68,042
+7,051
+12% +$240K 0.03% 464
2015
Q1
$2.16M Buy
60,991
+8,727
+17% +$312K 0.03% 537
2014
Q4
$1.78M Buy
52,264
+11,966
+30% +$425K 0.02% 599
2014
Q3
$1.55M Sell
40,298
-8,443
-17% -$315K 0.02% 863
2014
Q2
$1.9M Sell
48,741
-10,099
-17% -$376K 0.02% 782
2014
Q1
$2.01M Buy
58,840
+23,480
+66% +$727K 0.03% 746
2013
Q4
$742K Buy
35,360
+4,753
+16% +$120K 0.01% 1019
2013
Q3
$719K Buy
30,607
+13,188
+76% +$375K 0.02% 1132
2013
Q2
$468K Buy
+17,419
New +$505K 0.01% 1382

Other funds holding MYGN

ProShare Advisors's MYGN Position: Q1 2026 in Review

ProShare Advisors reduced its Myriad Genetics (MYGN) stake by 25% in Q1 2026, selling an estimated $22.6K and leaving 13,350 shares worth $60.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1767.

ProShare Advisors first reported a position in MYGN in Q2 2013 and has held it in 52 quarters since. The position peaked at $2.97M in Q4 2015. 202 funds tracked by Wall St. Rank hold MYGN as of Q1 2026.

  • ProShare Advisors held 13,350 shares of Myriad Genetics worth $60.1K as of Q1 2026.
  • ProShare Advisors sold 4,347 Myriad Genetics shares in Q1 2026, an estimated $22.6K.
  • Myriad Genetics made up ﹤0.01% of ProShare Advisors's portfolio in Q1 2026, its #1767 holding.
  • ProShare Advisors first reported a position in Myriad Genetics in Q2 2013 and has held it in 52 quarters since.
  • ProShare Advisors's Myriad Genetics position peaked at $2.97M in Q4 2015.
  • 202 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2026.

Based on ProShare Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.